Chemists have created a new type of artificial cell that can communicate with other parts of the body. A study, published in Science Advances this month, describes a new type of artificial cell that can communicate with living cells.
“This work begins to bridge the divide between more theoretical ‘what is cellular life’ type of work and applicative, useful technologies,” said Sheref Mansy, Chemistry Professor at the University of Alberta and co-author of the study.
The artificial cells are made using an oil-water emulsion, and they can detect changes within their environments and respond by releasing protein signals to influence surrounding cells. This work is the first that can chemically communicate with and influence natural living cells. They started with bacteria, later moving to multicellular organisms.
“In the future, artificial cells like this one could be engineered to synthesizes and deliver specific therapeutic molecules tailored to distinct physiological conditions or illnesses–all while inside the body,” explained Sheref Mansy, professor in the University of Alberta’s Department of Chemistry,
Though the initial study was undertaken using a specific signalling system, the cells have applications in therapeutic use, going beyond traditional smart-drug delivery systems and allowing for an adaptable therapeutic.
Interested in the pharmaceutical industry and research community? Take a look at this short video to see how we bring science and business together.
The next five years will be the most promising in the fight against cancer with immunotherapies – such as CAR-T and moderating T-Cell approaches, and innate immunity therapies – delivering far better patient outcomes.
In the last five years, the industry has rapidly advanced its understanding of the body’s immune response and genetic markers. As a result, combination therapies – chemotherapies will continue to play an important role – are forecast to become an increasingly standardised treatment, with pharma keen to invest.
These newer options are bringing in transformative remission rates, and check-point inhibitors have already been seen to elicit long-term cures in patients, with success rates two-to-three times higher than standard chemotherapy approaches.
Over the next ten years, we will see significant breakthroughs as the industry’s understanding of the immune system improves. There are currently more than 130 biotechs – in addition to 20 big pharma companies – working on new therapies and it is believed the smaller companies are more aggressively bringing newer innovations to market. In the long run, pharma will undoubtedly absorb the most promising players in an effort to become leaders in combination therapy approaches, which many argue will deliver the best outcomes.
The current investor frenzy is comparable to that of the genomics industry at the turn of the century. Experts argue that a more complete understanding of the genome and promise of clinical data of these transformative modalities will create a golden age for cancer therapy over the next few years.
There are, however, a number of immediate challenges. For example, CAR-T, although demonstrating good efficacy in blood cancers, has yet to show enough efficacy in solid tumours. Another challenge is how far towards cures for all patients we can get, particularly for patients with late stage metastatic cancer.
Immunotherapies are moving cancer from treatment options that simply extend life or improve experience to more effective cures. The cost of newer therapies is also coming into focus; however, this is a positive pressure on companies to produce significant, not just incremental, outcomes for patients.